Quick answer: Adderall contains amphetamine, so an amphetamine screen that flags it is a true positive, not a lab error. A Medical Review Officer (MRO) then decides whether the use was authorized. The DOT initial cutoff is 500 ng/mL. Confirmation testing by GC-MS/MS or LC-MS/MS settles the result.
- The DOT confirmatory cutoff for amphetamine is 250 ng/mL, following a 500 ng/mL initial immunoassay cutoff.
- Under 49 CFR 40.137, a legitimate medical explanation, such as a valid prescription, lets the MRO verify the result negative.
- American Screening Corp provides this guide; it is for program administrators and is not medical or legal advice.
Reviewed by the American Screening Corp product team, November 2026. Updated for the current federal cutoffs and detection-window research where the article cites them.
Adderall is a brand name for a mixture of amphetamine salts, so an amphetamine (AMP) drug screen that flags a person taking Adderall is reading the specimen correctly. That is a true positive for the substance amphetamine, not a lab error. What determines whether the result becomes a workplace problem is a separate, structured step called Medical Review Officer (MRO) verification, which distinguishes documented prescription use from unauthorized use before any result is reported to an employer.
This article explains the pharmacology behind the positive, the MRO process that resolves it, the other substances that genuinely can cross-react on an immunoassay screen, and why confirmation testing is the final word. It is written for HR, safety, and program administrators, not as guidance for donors on how to respond to a result.
Adderall Is Amphetamine, So a Positive Screen Is Expected
Adderall and Adderall XR contain dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate, a combination the FDA label describes as mixed salts of a single-entity amphetamine product. It is a Schedule II controlled substance approved for attention deficit hyperactivity disorder and narcolepsy.1 Immunoassay AMP panels are designed to detect exactly this class of molecule, so a person taking a therapeutic dose of Adderall as prescribed is expected to produce an amphetamine positive on a urine screen.
Need drug tests for your clinic, program or workplace?
American Screening Corp has supplied FDA-cleared, CLIA-waived tests at wholesale pricing since 2004. Popular options:
Ordering 100+ tests? Request volume pricing.
Under 49 CFR 40.85, the DOT-regulated cutoff for an initial amphetamine/methamphetamine immunoassay is 500 ng/mL, with a confirmatory GC-MS/MS or LC-MS/MS cutoff of 250 ng/mL for amphetamine (a specimen reported positive for methamphetamine must also contain amphetamine at or above 100 ng/mL).2 Many non-DOT employer programs use comparable cutoffs. These thresholds exist so that trace, incidental exposure does not trigger a reportable result, but a normal therapeutic Adderall dose is well above them.
The Result Is Not "False" Because It Screens Positive
Calling an Adderall-driven AMP positive a "false positive" misdescribes what happened. The screen correctly detected amphetamine. The question employers actually need answered is whether that amphetamine use was authorized, and that determination is not made by the testing device or the lab. It is made by a Medical Review Officer, a licensed physician trained to review laboratory results and interview the donor before any result is reported.
SAMHSA's Mandatory Guidelines for Federal Workplace Drug Testing Programs establish the scientific and technical framework federal agencies use, and equivalent MRO review procedures govern DOT-regulated, safety-sensitive testing.3 Under 49 CFR 40.137, once a laboratory reports a confirmed positive, the MRO must verify it positive unless the employee presents a legitimate medical explanation for the drug or metabolite found, such as a legally valid prescription. The MRO "must not question whether the prescribing physician should have prescribed the substance." The employee carries the burden of presenting that explanation at the verification interview, and if the MRO determines a legitimate medical explanation exists, the MRO must verify the test result as negative.4
In practice, this means an employee with a current, verifiable Adderall prescription who reports it during the MRO interview will typically have the amphetamine result verified negative for reporting purposes, provided the prescription is legitimate and consistent with the lab findings. Employers never see the underlying medical detail; they receive only the MRO's final verified result.
Genuine Cross-Reactivity: What Actually Produces a Wrong Amphetamine Screen
There is a real, separate phenomenon that deserves the "false positive" label: immunoassay antibodies binding to compounds that share structural features with amphetamine but are not amphetamine at all. Amphetamine-class molecules share a phenyl ring connected to an amino group by a two-carbon side chain, a structure found in several other legal substances, which is the mechanism behind cross-reactivity on presumptive immunoassay testing.5
Documented cross-reactants on amphetamine immunoassays include the decongestants pseudoephedrine and phenylephrine, the smoking-cessation and antidepressant drug bupropion (cross-reactivity reported in the 3 percent to 17 percent range depending on concentration in published assay evaluations), a trazodone metabolite called meta-chlorophenylpiperazine, and the Parkinson's/depression medication selegiline.5,6,7 None of these substances are amphetamine, and none of them will confirm as amphetamine on a proper laboratory confirmation test.
Screening Versus Confirmation Testing
| Factor | Immunoassay Screen (Point of Collection or Lab) | Lab Confirmation (GC-MS/MS or LC-MS/MS) |
|---|---|---|
| What it measures | Antibody binding to a class of structurally similar molecules | Exact molecular identification and quantification |
| Susceptible to cross-reactivity | Yes, for compounds sharing amphetamine's core structure | No, confirmation identifies the specific molecule present |
| Typical DOT cutoff, amphetamine | 500 ng/mL initial2 | 250 ng/mL confirmatory2 |
| Result type | Presumptive, non-negative | Definitive positive or negative |
| Required before adverse action | Not sufficient on its own for a non-negative result | Yes, non-negative screens must be confirmed before verification |
| Who interprets the confirmed result | Not applicable | Medical Review Officer, with donor interview |
Confirmatory methods such as GC-MS offer far greater specificity and sensitivity than immunoassay screening and are the accepted way to resolve a presumptive result definitively, which is why non-negative screens are never reported to an employer as a final result on their own.5 ASC's laboratory and reference lab testing supplies support this confirmation step in the overall testing chain.
Building an Amphetamine-Ready Testing Program
Employers running amphetamine screening, whether for DOT-regulated transportation testing, general workplace drug testing, or pre-employment screening, should have a written policy that spells out three things clearly before a single test is collected: how non-negative screens are routed to confirmation, who serves as the MRO or MRO-equivalent reviewer for non-DOT programs, and how prescription information is collected and kept confidential. Programs that skip a documented MRO or MRO-equivalent step risk treating a presumptive screen as a final answer, which is where most disputes and legal exposure originate, not from the initial AMP panel itself.
Multi-panel drug testing cups that include an AMP panel are a standard front-line tool for this workflow. Because the screen is only the first step, a program is only as defensible as its confirmation and review process behind it.
Medical and Legal Disclaimer
Drug test screening devices, including amphetamine panels, provide preliminary, presumptive results only. Any non-negative screening result must be sent to a certified laboratory for confirmation using a method such as GC-MS or LC-MS before it is treated as final, and confirmed non-negative results should be reviewed by a qualified Medical Review Officer or equivalent reviewer before any employment action is taken. This article is for general educational purposes for testing program administrators and is not medical advice, legal advice, or a substitute for consulting a physician, MRO, or qualified employment counsel about a specific case.
Frequently Asked Questions
If an employee takes Adderall as prescribed, will their drug test always show amphetamine?
A therapeutic Adderall dose is expected to produce an amphetamine-positive result on an immunoassay screen, because Adderall's active ingredients are amphetamine and dextroamphetamine. That result is accurate. What determines the final reported outcome is Medical Review Officer verification, where a documented, legitimate prescription can result in the test being verified negative for reporting purposes.
Is an Adderall-related amphetamine positive considered a false positive?
No. The screen correctly detects amphetamine, which is a true positive for that substance. It only becomes a "false positive" story colloquially when people confuse a true chemical detection with an unauthorized-use finding. The distinction between authorized and unauthorized amphetamine use is made through MRO review, not by the screening device.
What substances can actually cause a wrong amphetamine result on a screening test?
Documented cross-reactants on amphetamine immunoassays include pseudoephedrine, phenylephrine, bupropion, a trazodone metabolite, and selegiline, because these compounds share structural features with amphetamine that some antibody-based screens can bind to. None of these will confirm as amphetamine on a GC-MS or LC-MS laboratory confirmation test, which is why confirmation testing exists.
Can an employer see the details of an employee's prescription during MRO review?
No. Under 49 CFR 40.137, the employee presents their legitimate medical explanation, such as a prescription, directly to the Medical Review Officer during a confidential verification interview. The employer receives only the MRO's final verified result, not the underlying medical or prescription details.
Sources
- dailymed.nlm.nih.gov
- law.cornell.edu
- samhsa.gov
- law.cornell.edu
- ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
Related reading
How Long Does Adderall Stay Detectable? Detection Windows by Specimen
American Screening Corp reports detection windows as general ranges, not guarantees. Dose, formulation, urine pH, kidney function and frequency of use all change them. Immunoassay screens flag amphetamines at a set cutoff, so a result below the cutoff reads negative even if a trace remains.
| Specimen | Typical window after last dose | Common screening cutoff | Typical use |
|---|---|---|---|
| Urine | About 2 to 4 days | 1,000 ng/mL (HHS-style initial test) | Employment, clinics, probation |
| Oral fluid | About 1 to 2 days | 50 ng/mL (HHS oral fluid initial test) | Observed, on-site collection |
| Hair | Up to about 90 days | Laboratory-set | Long look-back |
Cutoffs are listed in the HHS Mandatory Guidelines (SAMHSA, as of 2024). Confirm the cutoff printed on your kit's package insert before you buy.
What Happens After a Positive Amphetamine Screen on a Prescription
A positive screen is preliminary; confirm by GC/MS or LC-MS/MS laboratory testing. Screening cannot tell prescribed Adderall from other amphetamine sources. The steps below are the usual path for regulated and many private programs.
- Record the preliminary result and keep the specimen's chain of custody intact.
- Send the specimen to a laboratory for GC/MS or LC-MS/MS confirmation.
- A Medical Review Officer (MRO) contacts the donor to ask about a valid prescription.
- The MRO decides whether the result is verified positive or verified negative, using the lab report and medical information.
- The employer receives only the verified result, not the diagnosis or medication details.
For DOT-regulated testing, 49 CFR Part 40 sets the MRO's role (Subpart G). Non-DOT programs should follow their written policy and applicable state law.
Policy Points Clinics, Employers and Courts Should Document
- Disclosure process: tell staff how and when to share prescription information with the MRO, not with supervisors.
- Confirmation rule: require lab confirmation before any adverse action on a presumptive positive.
- Cutoff and specimen: state which test, cutoff (ng/mL) and specimen type your program uses.
- Non-stimulant ADHD medicines: these are a different drug class and are not what an amphetamine panel targets.
- Legal review: have counsel check state statutes and ADA obligations on prescription medications.
American Screening Corp supplies FDA-cleared, CLIA-waived amphetamine tests in single and multi-panel formats, with lab confirmation and same-day shipping nationwide. This is general information, not medical or legal advice.
